Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

411 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.
de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM; BEACON Trial Investigators. de Zeeuw D, et al. N Engl J Med. 2013 Dec 26;369(26):2492-503. doi: 10.1056/NEJMoa1306033. Epub 2013 Nov 9. N Engl J Med. 2013. PMID: 24206459 Free PMC article. Clinical Trial.
Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.
Fellström BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, Floege J, Hetzel G, Jardine AG, Locatelli F, Maes BD, Mercer A, Ortiz F, Praga M, Sørensen SS, Tesar V, Del Vecchio L; NEFIGAN Trial Investigators. Fellström BC, et al. Among authors: praga m. Lancet. 2017 May 27;389(10084):2117-2127. doi: 10.1016/S0140-6736(17)30550-0. Epub 2017 Mar 28. Lancet. 2017. PMID: 28363480 Free article. Clinical Trial.
Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes.
Porrini E, Ruggenenti P, Mogensen CE, Barlovic DP, Praga M, Cruzado JM, Hojs R, Abbate M, de Vries AP; ERA-EDTA diabesity working group. Porrini E, et al. Among authors: praga m. Lancet Diabetes Endocrinol. 2015 May;3(5):382-91. doi: 10.1016/S2213-8587(15)00094-7. Lancet Diabetes Endocrinol. 2015. PMID: 25943757
Vitamin D receptor activation and cardiovascular disease.
Gonzalez-Parra E, Rojas-Rivera J, Tuñón J, Praga M, Ortiz A, Egido J. Gonzalez-Parra E, et al. Among authors: praga m. Nephrol Dial Transplant. 2012 Dec;27 Suppl 4:iv17-21. doi: 10.1093/ndt/gfs534. Nephrol Dial Transplant. 2012. PMID: 23258805 Review.
Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease.
de Vries AP, Ruggenenti P, Ruan XZ, Praga M, Cruzado JM, Bajema IM, D'Agati VD, Lamb HJ, Pongrac Barlovic D, Hojs R, Abbate M, Rodriquez R, Mogensen CE, Porrini E; ERA-EDTA Working Group Diabesity. de Vries AP, et al. Among authors: praga m. Lancet Diabetes Endocrinol. 2014 May;2(5):417-26. doi: 10.1016/S2213-8587(14)70065-8. Lancet Diabetes Endocrinol. 2014. PMID: 24795255 Review.
Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
Fernandez Juarez G, Luño J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M, Cachofeiro V, Nieto J, Fernández Vega F, Tato A, Gutierrez E; PRONEDI Study Group. Fernandez Juarez G, et al. Among authors: praga m. Am J Kidney Dis. 2013 Feb;61(2):211-8. doi: 10.1053/j.ajkd.2012.07.011. Epub 2012 Aug 29. Am J Kidney Dis. 2013. PMID: 22939518 Clinical Trial.
411 results